Pulmatrix Inc
(NASDAQ : PULM)

( )
PULM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.55%73.740.9%$598.99m
CELGCelgene Corporation
-0.84%129.191.1%$425.21m
AMGNAmgen Inc.
-0.63%169.001.1%$397.19m
BIIBBiogen Inc.
-1.42%282.641.2%$346.45m
REGNRegeneron Pharmaceuticals, Inc.
-0.31%477.152.7%$319.17m
VRTXVertex Pharmaceuticals Incorporated
-1.43%153.251.9%$227.49m
ALXNAlexion Pharmaceuticals, Inc.
-1.83%135.671.9%$211.59m
ILMNIllumina, Inc.
-0.59%193.623.5%$208.34m
KITEKite Pharma, Inc.
1.63%138.1716.1%$135.10m
INCYIncyte Corporation
-0.17%123.652.6%$130.04m
CLVSClovis Oncology, Inc.
-0.68%71.6118.0%$125.25m
TSROTESARO, Inc.
-0.18%120.4014.7%$124.85m
AAgilent Technologies, Inc.
-0.30%62.771.5%$122.45m
BMRNBioMarin Pharmaceutical Inc.
-0.07%81.404.4%$105.16m
SRPTSarepta Therapeutics, Inc.
-2.38%36.0719.8%$88.80m

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. It designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Edwards, Mark Gabrielson, Alexander Klibanov, and Robert Langer in 2013 and is headquartered in Lexington, MA.